Analytical Data
-
Gene name
PSG2
- Application
-
Alternative Names
PSG2;PSBG2;Pregnancy-specific beta-1-glycoProtein 2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P11465
-
Expression Region
35-335aa
-
AA Sequence
QVTIEAQPPKVSEGKDVLLLVHNLPQNLTGYIWYKGQIRDLYHYITSYVV DGQIIIYGPAYSGRE TAYSNASLLIQNVTREDAGSYTLHIIKRGDGTRGVTGYFTFTLYLETPKP SISSSNLNPREAMET VILTCDPETPDTSYQWWMNGQSLPMTHRFQLSETNRTLFLFGVTKYTAGP YECEIRNSGSASRSD PVTLNLLHGPDLPRIHPSYTNYRSGDNLYLSCFANSNPPAQYSWTINGKF QQSGQNLFIPQITTK HSGLYVCSVRNSATGEESSTSLTVKVSASTRIGLLPLLNPTVDHHHHHH
-
Molecular Weight
35 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PSG2, or pregnancy-specific glycoprotein 2, is a member of the pregnancy-specific glycoprotein (PSG) family, which is primarily expressed in the placenta during pregnancy. Research on PSG2 has gained significance due to its potential roles in immunomodulation, fetal development, and its association with various pregnancy-related complications. In early pregnancy, PSG2 may facilitate the mother’s immune tolerance towards the semi-allogeneic fetus, promoting a successful gestation. Additionally, abnormal levels of PSG2 have been linked to conditions such as pre-eclampsia and intrauterine growth restriction, making it a potential biomarker for monitoring pregnancy health. The recombinant form of PSG2 is being studied for its structural and functional properties, which may shed light on its mechanistic roles in maternal-fetal interactions. Understanding the molecular functions of PSG2 could lead to novel therapeutic strategies for managing pregnancy complications and enhancing pregnancy outcomes. Furthermore, PSG2 may hold promise in developing diagnostic tools for early detection of pregnancy-related disorders, emphasizing the importance of ongoing research in this area. Thus, the study of PSG2 and its recombinant protein not only contributes to our understanding of placental biology but also opens avenues for medical advancements in reproductive health.











